For example, brentuximab vedotin (A), an anti-CD30 antibody–drug conjugate that was initially approved for relapsed and refractory cHL, has been recently incorporated into the AVD regimen (A+AVD), with a reported survival advantage compared to the traditional AVD plus bleomycin scheme (ABVD) in advanced-stage cHL [5]. Here, TNFRSF8 is linked to classic Hodgkin lymphoma.